CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results. In-life portion of the repeat dose toxicology studies have been completed, and the results are being an
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://mmpconnect.com/enveric-biosciences-reports-year-end-progress-for-preclinical-development-of-lead-prodrug-candidate-eb-373/?utm_source=rss&utm_medium=rss&utm_campaign=enveric-biosciences-reports-year-end-progress-for-preclinical-development-of-lead-prodrug-candidate-eb-373
